Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma

ClinicalTrials.gov ID

NCT06375044

Lead Sponsor

Jiangsu Simcere Pharmaceutical Co., Ltd.INDUSTRY

Overall Status

Recruiting

Study Type

Interventional

Phase

Phase 1

Enrollment

130Estimated

Last Update Posted

Aug 28, 2026Actual

Start Date

May 24, 2024Actual

Primary Completion Date

Sep 30, 2027Estimated

Completion Date

Dec 30, 2028Estimated

Official Title

A Phase I First-in-human, Open-label Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0500, A Humanized GPRC5D-BCMA-CD3 Tri-specific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma

Brief Summary

This is an open-label, multicenter phase 1 clinical trial to evaluate the safety and tolerability, efficacy, and pharmacokinetics of SIM0500 in adult participants with Relapsed or Refractory Multiple Myeloma(RRMM). The trial is consisted of two parts, Part 1 (dose escalation) and Part 2 (dose optimization). In both parts, SIM0500 will be administered until disease progression, intolerable toxicity, withdraw of consent or end of trial.

• Relapsed or Refractory Multiple Myeloma

• SIM0500

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

1. Voluntary participation and signature of informed consent form.
2. ≥18 years of age.
3. Have documented diagnosis of relapsed or refractory multiple myeloma according to Criteria for Response to Multiple Myeloma Treatment(IMWG)diagnostic criteria who have failed all established standard of care.
4. Life expectancy ≥12 weeks.
5. Eastern Cooperative Oncology Group (ECOG) score of 0 or 1.
6. Adequate hematologic, hepatic, and renal function.

Exclusion Criteria:

1. Toxicities from previous anticancer therapies should have resolved to baseline levels or to Grade 1 or less except for alopecia or peripheral neuropathy.
2. Active hepatitis B (HBsAg positive and HBV DNA ≥ 1×104 copies/mL or ≥ 2,000 international unit [IU]/mL) or hepatitis C (HCV antibody positive and HCV RNA ≥ ULN) infection; participant with HBsAg positive or detective HBV-DNA at screening should receive antiviral treatment as per local practice during the trial.
3. Known human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome (AIDS).
4. Participant is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial.
5. Active known or suspected autoimmune disease. Participants with vitiligo, residual hypothyroidism only requiring hormone replacement, psoriasis not requiring systemic treatment or conditions not expected to recur in the absence of an external trigger, type 1 diabetes mellitus (blood glucose can be controlled by insulin therapy) can be included.
6. Current or previous other malignancy within 3 years of study entry, except basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the prostate, cervix or breast.
7. Known active central nervous system (CNS) involvement or exhibits clinical signs of meningeal involvement of multiple myeloma.
8. Participants with known active infection within 14 days prior to the first SIM0500.

Primary Purpose

Treatment

Allocation

N/A

Interventional Model

Sequential Assignment

Masking

None (Open Label)

Lead Sponsor

Jiangsu Simcere Pharmaceutical Co., Ltd.INDUSTRY

Collaborators

Shanghai Xianxiang Medical Technology Co., Ltd.INDUSTRY

855-776-0015

855-776-0015

clinicaltrials@simceregroup.com8573330740

• Study to Evaluate the Safety and Tolerability of CC-92328 in Participants With Relapsed and/or Refractory Multiple Myeloma

  NCT04975399

  TerminatedInterventionalPhase 1Updated Mar 24, 2025
• A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors

  NCT06792552

  RecruitingInterventionalPhase 1Updated Aug 17, 2026
• A Clinical Study of CT0596 CAR-T in Relapsed/Refractory Multiple Myeloma

  NCT07760454

  Not yet recruitingInterventionalPhase 1Phase 2Updated Aug 12, 2026
• A Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma

  NCT06049290

  RecruitingInterventionalPhase 1Phase 2Updated Sep 11, 2026
• A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma

  NCT06153251

  RecruitingInterventionalPhase 1Updated Mar 18, 2026
• SL4903 CAR-T Therapy for Relapsed/Refractory Multiple Myeloma

  NCT07234721

  Not yet recruitingInterventionalEarly Phase 1Updated Feb 10, 2026